Treatment of alcohol use disorders in patients with liver disease.
作者： Alain Braillon
DOI: 10.1016/J.JHEP.2016.07.049
关键词: Alcohol 、 Internal medicine 、 Liver disease 、 Alcohol and health 、 In patient 、 Medicine
摘要:
journal-of-hepatology.eu
sci-hub.se 参考文章(5)
Alain Braillon, Bernard Granger, Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing? Substance Abuse and Rehabilitation. ,vol. 6, pp. 75- 80 ,(2015) , 10.2147/SAR.S86007
A. Braillon, Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency BMJ. ,vol. 348, ,(2014) , 10.1136/BMJ.G2017
Clément Palpacuer, Bruno Laviolle, Rémy Boussageon, Jean Michel Reymann, Eric Bellissant, Florian Naudet, Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials PLOS Medicine. ,vol. 12, pp. e1001924- ,(2015) , 10.1371/JOURNAL.PMED.1001924
Giovanni Addolorato, Antonio Mirijello, Pablo Barrio, Antoni Gual, Treatment of alcohol use disorders in patients with alcoholic liver disease. Journal of Hepatology. ,vol. 65, pp. 618- 630 ,(2016) , 10.1016/J.JHEP.2016.04.029
Niamh Fitzgerald, Kathryn Angus, Andrew Elders, Marisa Andrade, Duncan Raistrick, Nick Heather, Jim McCambridge, Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers Addiction. ,vol. 111, pp. 1477- 1487 ,(2016) , 10.1111/ADD.13438